Impact of multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors

Neuroendocrinology

Volumn 91, Issue 1, 2010, Pages 101-109

  Ruf, Juri ^a   Heuck, Friederike ^b   Schiefer, Jan ^a   Denecke, Timm ^b   Elgeti, Florian ^b   Pascher, Andreas ^b   Pavel, Marianne ^b   Stelter, Lars ^b,c   Kropf, Siegfried ^a   Wiedenmann, Bertram ^b   Amthauer, Holger ^a,b  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

68Ga DOTATOC; Detection rate; Multiphase CT; Neuroendocrine tumor; PET; PET CT; Therapy management

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID PHENYLALANYLTYROSYL OCTREOTIDE GA 68; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IOPROMIDE; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GA(III) DOTATOC; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRACHYTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; EVALUATION; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 76749170715     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000265561     Document Type: Article

References (34)

1. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, O'Carroll AM, Patel YC, Schonbrunn A, Taylor JE, Reisine T: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
2. Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24: 389-427.
3. Reubi JC: Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995; 36: 1825-1835.
4. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27: 273-282.
5. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A: Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68 Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 48-52.
6. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al: Somatostatin receptor scintigraphy with [ 111 In-DTPA- D -Phe1]- and [ 123 I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993; 20: 716-731.
7. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004; 151: 15-27.
8. Cherry SR, Sorenson SA, Phelps M: Physics in Nuclear Medicine, ed 3. Philadelphia, Saunders, 2003.
9. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H: Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007; 34: 982-993.
10. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H: Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
11. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U: Comparison of 68 Ga-DOTATOC PET and 111 In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-1626.
12. Kowalski J, Henze M, Schuhmacher J, et al: Evaluation of positron emission tomography imaging using [ 68 Ga]-DOTA- D- Phe(1)- Tyr(3)-octreotide in comparison to [ 111 In]- DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003; 5: 42-48.
13. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ: 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
14. Mawlawi O, Townsend DW: Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009; 36(suppl 1):15-29.
15. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ: Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga- DOTATATE (DOTA- D- Phe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008; 112: 2447-2455.
16. Elgeti F, Amthauer H, Denecke T, Steffen I, Heuck F, Stelter L, Ruf J: Incidental detection of breast cancer by 68 Ga-DOTATOC-PET/ CT in women suffering from neuroendocrine tumours. Nuklearmedizin 2008; 47: 261-265.
17. Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G: Intraindividual comparison of 68 Ga-DOTA-TATE and 18 F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009; 36: 765-770.
18. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, Jahn M, Jennewein M, Rösch F: Processing of generatorproduced 68 Ga for medical application. J Nucl Med 2007; 48: 1741-1748.
19. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U: ENETS Guidelines for the Standards of Care in Patients with Neuroendocrine Tumours: Radiological examinations in patients with neuroendocrine tumours. Neuroendocrinology 2009; 90: 167-183.
20. SAS/STAT® 9.2 User's Guide. Cary, SAS Institute Inc., USA, 2008.
21. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ: Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/ CT and PET/MRI. Eur J Med Res 2006; 11: 58-65.
22. Seemann MD: Detection of metastases from gastrointestinal neuroendocrine tumors: prospective comparison of 18 F-TOCA PET, triple-phase CT, and PET/CT. Technol Cancer Res Treat 2007; 6: 213-220.
23. Meisetschläger G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M: Gluc-Lys([ 18 F]FP)- TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [ 111 In]DTPA-octreotide. J Nucl Med 2006; 47: 566-573.
24. Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, Wester HJ: First 18 Flabeled tracer suitable for routine clinical imaging of SST receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004; 10: 3593-3606.
25. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA: Comparison between 18 F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005; 46: 587-595.
26. Krishnasetty V, Fischman AJ, Halpern EL, Aquino SL: Comparison of alignment of computer-registered data sets: combined PET/CT versus independent PET and CT of the thorax. Radiology 2005; 237: 635-639.
27. Weigert M, Pietrzyk U, Müller S, Palm C, Beyer T: Whole-body PET/CT imaging: combining software- and hardware-based co-registration. Z Med Phys 2008; 18: 59-66.
28. van Dalen JA, Visser EP, Vogel WV, Corstens FH, Oyen WJ: Impact of Ge-68/Ga-68-based versus CT-based attenuation correction on PET. Med Phys 2007; 34: 889-897.
29. Goerres GW, Burger C, Kamel E, Seifert B, Kaim AH, Buck A, Buehler TC, Von Schulthess GK: Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology 2003; 226: 906-910.
30. Prabhakar HB, Sahani DV, Fischman AJ, Mueller PR, Blake MA: Bowel hot spots at PET-CT. Radiographics 2007; 27: 145-159.
31. Pape UF, Böhmig M, Berndt U, Tiling N, Wiedenmann B, Plöckinger U: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann N Y Acad Sci 2004; 1014: 222-233.
32. Oliver JH 3rd, Baron RL, Federle MP, Jones BC, Sheng R: Hypervascular liver metastases: do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology 1997; 205: 709-715.
33. Hukovic N, Panetta R, Kumar U, Patel YC: Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996; 137: 4046-4049.
34. Yalcin S, Oyan B, Bayraktar Y: Current medical treatment of pancreatic neuroendocrine tumors. Hepatogastroenterology 2007; 54: 278-284.